Kyu-Sun Choi1, Youngsuk Cho2, Bo-Hyoung Jang3, Wonhee Kim2, Chiwon Ahn4, Tae Ho Lim4, Hyoung-Joong Yi1. 1. Department of Neurosurgery, College of Medicine, Hanyang University, Seoul, Republic of Korea. 2. Department of Emergency Medicine, College of Medicine, Hallym University, Seoul, Republic of Korea; Department of Biomedical Engineering, College of Medicine, Hanyang University, Republic of Korea. 3. Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea. Electronic address: bhjang@khu.ac.kr. 4. Department of Emergency Medicine, College of Medicine, Hanyang University, Seoul, Republic of Korea.
Abstract
PURPOSE: Copeptin, the C-terminal portion of provasopressin, has emerged as a novel prognostic marker in neurocritical care, such as in traumatic brain injury (TBI). The aim of this study was to quantitatively assess the prognostic significance of initial plasma copeptin levels in the neurological outcome and mortality after traumatic brain injury. MATERIALS AND METHODS: Six relevant studies with data from 552 patients were included in this meta-analysis. RESULTS: The plasma copeptin levels were found to be significantly higher in patients who died than in the survivors (standardized mean difference [SMD], 1.80). In the four studies reporting Glasgow outcome scale (GOS) data, patients with unfavorable outcomes had significantly higher copeptin levels than those with favorable outcomes (SMD, 1.62). The plasma copeptin level predicted mortality and unfavorable outcomes (AUC, 0.873; AUC, 0.876). CONCLUSIONS: The present meta-analysis suggests that early measurement of plasma copeptin levels can provide better prognostic information about the functional outcome and mortality in patients with TBI.
PURPOSE:Copeptin, the C-terminal portion of provasopressin, has emerged as a novel prognostic marker in neurocritical care, such as in traumatic brain injury (TBI). The aim of this study was to quantitatively assess the prognostic significance of initial plasma copeptin levels in the neurological outcome and mortality after traumatic brain injury. MATERIALS AND METHODS: Six relevant studies with data from 552 patients were included in this meta-analysis. RESULTS: The plasma copeptin levels were found to be significantly higher in patients who died than in the survivors (standardized mean difference [SMD], 1.80). In the four studies reporting Glasgow outcome scale (GOS) data, patients with unfavorable outcomes had significantly higher copeptin levels than those with favorable outcomes (SMD, 1.62). The plasma copeptin level predicted mortality and unfavorable outcomes (AUC, 0.873; AUC, 0.876). CONCLUSIONS: The present meta-analysis suggests that early measurement of plasma copeptin levels can provide better prognostic information about the functional outcome and mortality in patients with TBI.
Authors: Joachim Düring; Martin Annborn; Tobias Cronberg; Josef Dankiewicz; Yvan Devaux; Christian Hassager; Janneke Horn; Jesper Kjaergaard; Michael Kuiper; Homa Rafi Nikoukhah; Pascal Stammet; Johan Undén; Michael Jaeger Wanscher; Matt Wise; Hans Friberg; Niklas Nielsen Journal: Crit Care Date: 2020-04-28 Impact factor: 9.097
Authors: Fulvio Salvo; Francesco Luppi; Davide M Lucchesi; Simone Canovi; Stefano Franchini; Alessandra Polese; Francesca Santi; Laura Trabucco; Tommaso Fasano; Anna Maria Ferrari Journal: BMC Emerg Med Date: 2020-02-24